Caribou Biosciences (CRBU) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Serina Therapeutics (SER) has outperformed Caribou Biosciences (CRBU) over the past year, losing 64.3% versus a loss of 82.0%. Over five years, SER leads with a -93.9% price change compared with -97.7% for CRBU. Serina Therapeutics is the larger company by market cap ($50.5 million vs $49.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | SER |
|---|---|---|
| Share price | $0.4599 | $1.99 |
| Market cap | $49.30M | $50.55M |
| 1-day change | -4.43% | -1.00% |
| YTD return | -69.74% | +5.07% |
| 1-year return | -82.04% | -64.30% |
| 5-year return | -97.69% | -93.88% |
| EPS (TTM) | $-1.08 | $-1.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $5.60 |
| 52-week low | $0.45 | $1.22 |
| Distance from 52-week high | -86.99% | -64.46% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1150.27% | +377.39% |
| Average volume | 2.14M | 63.89K |
| Shares outstanding | 107.21M | 25.40M |
| Employees | 97 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SER has outperformed CRBU by 17.7 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CRBU vs SER FAQ
Which is bigger, Caribou Biosciences or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $50.55M compared with $49.30M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or SER?
SER returned -64.30% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Serina Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Caribou Biosciences and Biotechnology: Pharmaceutical Preparations for Serina Therapeutics.